Hypereosinophilia, hematologist Papayannidis “A new antibody improves patients' quality of life”

Hypereosinophilic syndrome: Ready to HES 2024, hosted in Turin, has the ambitious objective of differentiating and correctly classifying the disease, offering a model of methodological approach for the collection of clinical experiences at a national level. “Today we have an antibody available that acts against interleukin 5, which is the factor that determines the growth of eosinophils – states Dr. Cristina Papayannidis, Medical Director of the IRCCS AOU of Bologna – Institute of Hematology Seràgnoli – This antibody has the ability to modify and improve the symptoms that these patients may present, consequently improving their quality of life.”